The Pharma Letter4d
Driving innovation in blood cancer: Gilead and Kite Oncology’s vision for the Middle East
Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...
Les Echos Patrimoine5d
Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting
Sartorius Stedim Biotech's Board proposes a dividend of 0.69 euros per share for the fiscal year 2024, with two new Board candidates named. AGM scheduled for March 25, 2025 ...
BioSpace14d
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical ...
Investing14d
Newamsterdam pharma CFO sells shares worth $1.5 million
Mayur Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), a $2.24 billion market cap pharmaceutical company, recently executed several transactions involving the ...
Yahoo Finance14d
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...
Mena FN15d
Newamsterdam Pharma To Present At Guggenheim’S SMID Cap Biotech Conference
(MENAFN- GlobeNewsWire - Nasdaq) NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or ...
Business Insider16d
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target of $40.00. The company’s shares closed ...